Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<scp>SPIB</scp> is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the <scp>PI</scp>3K‐<scp>AKT</scp> pathway

27 Jun 2016

Abstract excerpt

Although the clinical outcomes of diffuse large B-cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one-third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initial treatment in order to select optimal therapies. Here, we investigated the clinical and biological significance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CNS Lymphoma Diagnosis and Treatment
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27348272
DOI: 10.1111/cas.13001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<scp>SPIB</scp> is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the <scp>PI</scp>3K‐<scp>AKT</scp> pathwayPMID 27348272Read ↗

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysSemantic proximity Read ↗

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.Semantic proximity Read ↗

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphomaSemantic proximity Read ↗

SYK inhibition and response prediction in diffuse large B-cell lymphomaSemantic proximity Read ↗

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphomaSemantic proximity Read ↗

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.Semantic proximity Read ↗

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasmsSemantic proximity Read ↗

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signallingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.